Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck
Autor: | Xavier Pivot, B Laguerre, L. Cals, M. Schneider, L. Kayitalire, V Ripoche, J L Lefebvre, Eric Raymond, D Gedouin, J Latz, M Degardin, J.P. Armand, C. Niyikiza, R Johnson |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2001 |
Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Guanine Neutropenia medicine.medical_treatment Antineoplastic Agents Pemetrexed head and neck squamous cell carcinoma chemotherapy Gastroenterology chemistry.chemical_compound LY231514 Glutamates Internal medicine medicine Mucositis Humans Enzyme Inhibitors pemetrexed disodium Aged Chemotherapy multitargeted antifolate business.industry Remission Induction Regular Article ALIMTA® Middle Aged medicine.disease Thrombocytopenia Surgery Oncology chemistry Epidermoid carcinoma Head and Neck Neoplasms Antifolate Carcinoma Squamous Cell Folic Acid Antagonists Female Neoplasm Recurrence Local business Febrile neutropenia Progressive disease medicine.drug |
Zdroj: | British Journal of Cancer |
ISSN: | 1532-1827 0007-0920 |
Popis: | This phase II study determined response rate of patients with locally advanced or metastatic head and neck cancer treated with pemetrexed disodium, a new multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase and glycinamide ribonucleotide formyl transferase. 35 patients with local or metastatic relapse of squamous cell carcinoma of the head and neck (31 male, 4 female; median age 53 years) were treated with pemetrexed 500 mg m2 administered as a 10-minute infusion on day 1 of a 21-day cycle. Patients received 1 to 8 cycles of therapy. 9 patients (26.5%) had an objective response, with a median response duration of 5.6 months (range 2.9–20 months). 15 (44.1%) had stable disease, and 8 (23.5%) had progressive disease. 2 patients were not assessable for response. Median overall survival was 6.4 months (range 0.7–28.1 months; 95% CI: 3.9–7.7 months). 24 patients (68.6%) experienced grade 3/4 neutropenia, with febrile neutropenia in 4 (11.4%). Grade 3/4 anaemia and thrombocytopenia occurred in 11 (34.3%) and 6 (17.1%) patients, respectively. The most frequent non-haematological toxicity was grade 3/4 mucositis (17.1%; 6 patients). In conclusion, pemetrexed is active in squamous cell carcinoma of the head and neck. Although substantial haematological toxicities were experienced by patients, subsequent studies have shown that these toxicities can be proactively managed by folic acid and vitamin B12 supplementation. © 2001 Cancer Research Campaign http://www.bjcancer.com |
Databáze: | OpenAIRE |
Externí odkaz: |